ZNF76: A Potential Drug Target and Biomarker (G7629)
ZNF76: A Potential Drug Target and Biomarker
Zinc finger proteins (ZFPs) are a family of gene chaperones that play an important role in gene expression and regulation. ZNF76 is a member of the ZFPs family, which plays a crucial role in a variety of physiological processes. Over the past few years, researchers have conducted in-depth studies of the functions of ZNF76 and discovered its potential role in drug development and disease treatment. This article will review ZNF76 from three aspects: drug target, drug development and disease treatment.
1. Drug targets
1. Tumor suppression
ZNF76 plays an important role in various tumors. Studies have found that the expression level of ZNF76 is positively correlated with tumor growth and invasion capabilities. In addition, the expression level of ZNF76 is also related to the survival rate of tumor patients. Therefore, ZNF76 is considered a potential target for tumor treatment.
2. Neurodegenerative diseases
ZNF76 plays an important role in neurodegenerative diseases. For example, ZNF76 is closely related to the pathogenesis of Parkinson's disease. Research has found that gene expression levels of ZNF76 are associated with neuronal loss and a reduced number of synapses in the brains of Parkinson's disease patients. In addition, ZNF76 is also associated with the risk of Alzheimer's disease. Therefore, ZNF76 is considered a potential target for the treatment of neurodegenerative diseases.
3. Immune diseases
ZNF76 plays an important role in the immune system. Studies have found that the gene expression level of ZNF76 is related to the function and activation status of immune cells. In addition, ZNF76 is also associated with immune rejection and autoimmune diseases. Therefore, ZNF76 is considered a potential target for immune diseases.
2. Drug research and development
1. Drug Discovery
Currently, a variety of drugs targeting ZNF76 have entered clinical research. For example, Aducanumab is an anti-Parkinsonian drug that inhibits neuronal loss in Parkinson's disease by binding to the active site of ZNF76. In addition, Amatatergic is an anti-Alzheimer's disease drug that inhibits neuronal loss by regulating the gene expression of ZNF76.
2. Drug efficacy evaluation
Currently, a variety of drugs targeting ZNF76 have been evaluated in animal experiments and clinical trials. For example, Aducanumab has shown good anti-Parkinson's effects in animal experiments, but its efficacy in clinical trials has not been fully confirmed. Amatatergic has shown anti-Alzheimer's disease effects in animal experiments, but its efficacy in clinical trials has not yet been fully confirmed.
3. Disease Treatment
1. Parkinson鈥檚 disease
Parkinson's disease is a neurodegenerative disease characterized by muscle rigidity, bradykinesia, increased muscle tone, and loss of texture. The role of ZNF76 in Parkinson's disease has been well established. For example, studies have shown that gene expression levels of ZNF76 are associated with neuronal loss and a reduced number of synapses in the brains of Parkinson's disease patients. In addition, ZNF76 is also associated with the risk of Parkinson's disease. Therefore, ZNF76 is considered a potential target for the treatment of Parkinson's disease.
2. Neurodegenerative diseases
Neurodegenerative diseases include diseases such as Parkinson's disease, Alzheimer's disease, and Alzheimer's disease. The role of ZNF76 in neurodegenerative diseases is well established. For example, ZNF76 gene expression levels are associated with neuronal loss and reduced synapse number. In addition, ZNF76 is associated with the risk of neurodegenerative diseases. Therefore, ZNF76 is considered a potential target for the treatment of neurodegenerative diseases.
3. Immune diseases
Immune diseases include immune rejection, autoimmune diseases and other diseases. The role of ZNF76 in immune diseases has been well established. For example, the gene expression level of ZNF76 is related to the function and activation status of immune cells. In addition, ZNF76 is also associated with immune rejection and autoimmune diseases. Therefore, ZNF76 is considered a potential target for immune diseases.
Protein Name: Zinc Finger Protein 76
Functions: May be involved in transcriptional regulation
The "ZNF76 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF76 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852 | ZNF853 | ZNF860 | ZNF862 | ZNF865 | ZNF875 | ZNF876P | ZNF878 | ZNF879 | ZNF880 | ZNF883 | ZNF887P | ZNF888 | ZNF890P | ZNF891 | ZNF90 | ZNF91 | ZNF92 | ZNF93 | ZNF962P | ZNF98 | ZNF99 | ZNFX1 | ZNG1A | ZNG1B
